Lucentis
Novartis’ Lucentis secures European approval for infants with rare eye disease
September 6, 2019Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
Roche’s eye drug beats Lucentis at Phase 2 in wet age-related macular degeneration
October 29, 2018Research and Development, Sales and Marketing Genentech, Lucentis, Roche, eyecare, faricimab, pharma
Roche has revealed positive new Phase 2 data for faricimab (RG7716) in the treatment of neovascular (“wet”) age-related macular degeneration …
Roche granted further good news by FDA
October 11, 2016Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america
Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …
Bayer’s complaint over ‘misleading’ Novartis eye drug claims upheld
August 14, 2015Medical Communications Bayer, Eylea, Lucentis, Novartis, PMCPA, code of conduct
The industry’s code of conduct regulator has ruled in favour of Bayer in a dispute claims made by Novartis when …
Novartis accused of Lucentis ‘campaign’ against Avastin
April 2, 2015Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD
Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …
Bayer and Regeneron eye drug gains another indication
March 26, 2015Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept
Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …
Doctors appeal to prescribe Avastin off-label
February 25, 2015Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD
NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …
FDA clears Roche eye drug
February 9, 2015Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab
The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …
EU looks at eye drug allegations
May 8, 2014Sales and Marketing EU, Lucentis, Novartis, Roche, avastin, offlabel
European Union regulators are considering whether they need to take any action over the recent allegations of anti-competitiveness involving Roche …
Roche/Novartis offices raided over anti-competitive activities
April 11, 2014Sales and Marketing Lucentis, Novartis, Roche, SHIP Cluster, avastin, wet AMD
French competition authorities are investigating Roche and Novartis in connection with their marketing of Lucentis for wet age-related macular degeneration …
NICE gives Lucentis more scope
November 27, 2013Sales and Marketing Lucentis, NICE, Novartis, cnv
An undisclosed price cut from Novartis has been enough to swing NICE towards using the manufacturer’s Lucentis in a fourth …
NICE ‘yes’ to Lucentis – with price cut
October 25, 2013Sales and Marketing Dillon, Lucentis, NICE, Novartis
A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …
Novartis launches Facebook ‘retina app’
October 15, 2013Medical Communications AMD, Bayer, Lucentis, Novartis, set your sights
Novartis, the world’s biggest eye-care drugmaker, has launched a new Facebook retina app to raise awareness of retinal disease. The …
Eylea receives new European approval
August 30, 2013Research and Development, Sales and Marketing Bayer, CRVO, Eylea, Lucentis, Novartis, wet AMD
Latest content
Artificial hearts: a century of innovation
